Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy,...

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with...

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular...

The FDA has granted accelerated approval to selpercatinib for adult patients with locally advanced or metastatic solid tumors harboring a RET gene fusion that...

The field of relapsed/refractory small cell lung cancer is expanding to include novel options for disease management, most notably, the chemotherapy...

OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in...

OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in...

June 17, 2022 | Aditya Bardia, MD, MPHVideo Player is loading.Current Time 0:00Duration 8:59Remaining Time 8:59Current Time 0:00Duration 0:00Remaining Time 0:00Video Player is loading.Current Time 0:00Duration 8:59Remaining Time 8:59Current...

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with...

  • 1573598253538590723 Profile photo of Madelyn

    Abemaciclib + a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer. @MayoClinic #ESMO2022 #bcsm https://t.co/PqSKBsiDCC - view on twitter

Pembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck...